| HOME >> BIOLOGY >> TECHNOLOGY |
Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, will present new findings today at the International Conference on Stem Cell Engineering (ICSCE). Analysis of the cells grown under Histogen's proprietary conditions of hypoxia and low gravity show the expression of specific markers associated with embryonic stem cells.
San Diego, CA (PRWEB) May 3, 2010 -- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, will present new findings today at the International Conference on Stem Cell Engineering (ICSCE). Analysis of the cells grown under Histogen's proprietary conditions of hypoxia and low gravity show the expression of specific markers associated with embryonic stem cells.
Different cell types can be identified by unique profiles based on the genes they express, the proteins they produce, and markers that they have on their cell surface. Histogen has discovered that, under growth conditions of 2-5% oxygen (hypoxia) and low gravity, safe and non-controversial newborn skin cells (fibroblasts) acquire the profile of pluripotent stem cells.
"Over 5,000 genes are differentially expressed by these cells, as compared to fibroblasts grown under traditional conditions," said Dr. Gail K. Naughton, CEO and Chairman of the Board at Histogen. "What we are seeing is a shift in the profile of these cells to one that is more embryonic-like, more similar to stem cells than fibroblasts."
DNA microarray analysis revealed that, under hypoxic culture conditions, fibroblasts upregulate the expression of key embryonic stem cell markers including Oct4, Nanog, and Sox2. These specific genes are known to be critical in the generation of induced pluripotent stem cells. A number of other stem cell-ass
'/>"/>
| Source: PRWeb Copyright©2010 Vocus, Inc. All rights reserved |